메뉴 건너뛰기




Volumn 4, Issue , 2010, Pages 18-19

How can we target pulmonary inflammation in cystic fibrosis?

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIBIOTIC AGENT; CATHEPSIN; CERAMIDE; CHLORIDE ION; GLYCYLPROLINE; HIGH MOBILITY GROUP B1 PROTEIN; LEUKOCYTE ELASTASE; MATRIX METALLOPROTEINASE; PROLYLGLYCYLPROLINE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SPHINGOMYELIN PHOSPHODIESTERASE; UNCLASSIFIED DRUG;

EID: 77953366200     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306401004020018     Document Type: Editorial
Times cited : (3)

References (6)
  • 1
    • 41849092177 scopus 로고    scopus 로고
    • Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis
    • Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008; 14(4): 382-91.
    • (2008) Nat Med , vol.14 , Issue.4 , pp. 382-391
    • Teichgräber, V.1    Ulrich, M.2    Endlich, N.3    Riethmüller, J.4    Wilker, B.5    de Oliveira-Munding, C.C.6
  • 2
    • 45949089501 scopus 로고    scopus 로고
    • A novel proteolytic cascade generates an extracellular matrix-derivedchemoattractant in chronic neutrophilic inflammation
    • Gaggar A, Jackson PL, Noerager BD, O'Reilly PJ, McQuaid DB, Rowe SM. A novel proteolytic cascade generates an extracellular matrix-derivedchemoattractant in chronic neutrophilic inflammation. J Immunol 2008; 180(8): 5662-9.
    • (2008) J Immunol , vol.180 , Issue.8 , pp. 5662-5669
    • Gaggar, A.1    Jackson, P.L.2    Noerager, B.D.3    O'Reilly, P.J.4    McQuaid, D.B.5    Rowe, S.M.6
  • 3
    • 54049139979 scopus 로고    scopus 로고
    • Potential role of high-mobility group box 1 in cystic fibrosis airway disease
    • Rowe SM, Jackson PL, Liu G, et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008; 178(8): 822-31.
    • (2008) Am J Respir Crit Care Med , vol.178 , Issue.8 , pp. 822-831
    • Rowe, S.M.1    Jackson, P.L.2    Liu, G.3
  • 4
    • 0037072766 scopus 로고    scopus 로고
    • Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination
    • Taggart CC, Greene CM, McElvaney NG, O'Neill S. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem 2002; 277(37): 33648-53.
    • (2002) J Biol Chem , vol.277 , Issue.37 , pp. 33648-33653
    • Taggart, C.C.1    Greene, C.M.2    McElvaney, N.G.3    O'Neill, S.4
  • 5
    • 2542533920 scopus 로고    scopus 로고
    • Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells
    • Greene CM, McElvaney NG, O'Neill SJ, Taggart CC. Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun 2004; 72(6): 3684-7.
    • (2004) Infect Immun , vol.72 , Issue.6 , pp. 3684-3687
    • Greene, C.M.1    McElvaney, N.G.2    O'Neill, S.J.3    Taggart, C.C.4
  • 6
    • 29144439305 scopus 로고    scopus 로고
    • Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding
    • Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005; 202(12): 1659-68.
    • (2005) J Exp Med , vol.202 , Issue.12 , pp. 1659-1668
    • Taggart, C.C.1    Cryan, S.A.2    Weldon, S.3    Gibbons, A.4    Greene, C.M.5    Kelly, E.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.